Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

Several other brokerages have also recently commented on BHVN. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Barclays PLC started coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 target price on the stock. William Blair started coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 target price on the stock. Piper Jaffray Companies started coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $21.00 target price on the stock. Finally, Needham & Company LLC started coverage on Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set a “buy” rating and a $30.00 target price on the stock. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Biohaven Pharmaceutical Holding Co has a consensus rating of “Buy” and an average price target of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) opened at 38.12 on Thursday. The company has a 50 day moving average price of $29.28 and a 200-day moving average price of $25.82. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $38.56. The firm’s market cap is $1.37 billion.

ILLEGAL ACTIVITY NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/10/biohaven-pharmaceutical-holding-co-ltd-bhvn-upgraded-to-strong-buy-by-bidaskclub.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.